EPID Research at ICPE 2016!
EPID Research is proud to sponsor the ICPE 2016 in Dublin and we look forward to meeting you at our booth #29! Also, you are welcome to book a private meeting with us!
Find out more: ICPE 2016
Real-World Evidence (RWE)
We provide pharmacoepidemiological research services for pharmaceutical companies, health care organizations and authorities. We study the actual use and effects of drugs in large numbers of people by utilizing population-wide health care registries. Our studies provide information on effectiveness, adverse effects and costs of drug treatment. Our methodology combines clinical, pharmacological, epidemiological and statistical knowledge.
We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.
Advantages for the customer
In our work we use reliable patient level information from existing national health registers. Studies performed by us do not require a massive study infrastructure because information accumulates in the data sources during normal health care procedures. Our process is fast, transparent, repeatable and traceable. This results in a cost-efficient way of evaluating the risk-benefit profiles of medical treatments.
For more information, please contact us.
News and publications
Our new article on pioglitazone use and risk of bladder cancer in patients with type 2 diabetes has been published in BMJ. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Published in BMJ 2016;354:i3903. Press Release - Article (16.8.2016)
Our recently published article on cardiac mortality and use of progestin for menopause in Journal of Endocrinology & Metabolism has been cited in the Duodecim publication (in Finnish) - Duodecim article (4.7.2016)
Our new article on cardiac mortality and use of progestin for menopause has been published. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies. Published in Journal of Endocrinology & Metabolism, doi: 10.1210/jc.2015-4149 - Article (12.5.2016)
EPID Multiple Sclerosis Pregnancy study - Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta - a register-based study in the Nordic countries. Study accepted in the ENCePP E-Register of studies. More detailed information about the study available here. (15.4.2016)
Our new article on mortality and use of certain basal insulins has been published. All-cause and cause-specific mortality among users of basal insulins NPH, detemir and glargine. Published in PLoS One 2016, doi:10.1371/journal.pone.0151910 - Article (31.3.2016)
Our new article finds that the use of vaginal estradiol is associated with significant reductions in the risk of death from coronary heart disease and stroke. Vaginal estradiol use and the risk for cardiovascular mortality. Published in Human Reproduction 2016, doi:10.1093/humrep/dew014 - Abstract (13.2.2016)
Melinda Manley Daumont presented the poster "Comparative effectiveness research of treatments for advanced melanoma in Europe using existing real-world data sources: A feasibility assessment" in the Society for Melanoma Research 2015 International Congress, 18-21 November 2015 - Poster - Abstract (23.11.2015)
Mika Lehto gave an oral presentation titled "Risk of stroke, bleeding events and mortality is strongly associated with the quality of warfarin therapy. Results from the FinWAF registry with 54,568 patients" in the American Heart Association's Scientific Session 2015, 12-16 November 2015. For further information, please see the abstract here and the congress dispatch article here (17.11.2015)
Want to get started? Eager to try us out? The best way to move forward is to put us to a test: we can help you to identify and evaluate relevant data sources and make a proposal for an actual study.
To learn more: